Traws Pharma (TRAW) awards CEO 231,336 stock options at $1.60

Rhea-AI Filing Summary

Traws Pharma, Inc. granted Chief Executive Officer Iain D. Dukes stock options covering 231,336 shares of common stock. The options have a $1.60 exercise price, were awarded at no cost, and will vest 100% on the first anniversary of the March 8, 2026 grant date. They expire on March 8, 2036 and represent compensation approved by the company’s independent compensation committee under its 2021 Incentive Compensation Plan, rather than an open-market share purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dukes Iain D.

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.6	03/08/2026		A		231,336		03/08/2027(1)	03/08/2036	Common Stock	231,336	$0	231,336	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Iain Dukes	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Traws Pharma (TRAW) disclose about its CEO’s latest equity compensation?

Traws Pharma disclosed that CEO Iain D. Dukes received stock options for 231,336 common shares as compensation. These options were granted at no cost, vest fully one year after the March 8, 2026 grant date, and give him the right to buy shares at a fixed exercise price.

How many stock options did the Traws Pharma (TRAW) CEO receive in this Form 4?

The CEO received stock options for 231,336 shares of Traws Pharma common stock. All these options were granted in a single award and represent the total derivative holdings reported after the transaction, giving him rights to purchase the same number of common shares once vested.

What is the exercise price and term of the Traws Pharma (TRAW) CEO’s new options?

The options carry an exercise price of $1.60 per share and expire on March 8, 2036. This means the CEO can choose to buy up to 231,336 shares at $1.60 each any time after vesting and before the expiration date, subject to plan terms.

When do the Traws Pharma (TRAW) CEO’s newly granted stock options vest?

The stock options vest 100% on the first anniversary of the grant date, March 8, 2026. This single vesting date structure means the CEO must remain eligible through that date to receive full rights to exercise all 231,336 options under the company’s incentive plan.

Under which plan were the Traws Pharma (TRAW) CEO’s options granted?

The options were granted under Traws Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated. The award was approved by the company’s compensation committee composed of independent directors, reinforcing that this is standard equity compensation rather than a market purchase or sale.

Did the Traws Pharma (TRAW) CEO buy or sell shares on the open market in this filing?

No open-market share purchases or sales were reported in this Form 4. Instead, the CEO received a grant of 231,336 stock options as compensation, at no cash cost, giving him future rights to acquire shares at a fixed exercise price if he chooses to exercise.